COMPANY
Endogena Therapeutics
Timeline
- Trial start Phase 1/Phase 2: Dose Escalation Study to Evaluate the Safety/Tolerability and Efficacy of EA-2353 in Subjects With Retinitis Pigmentosa source ↗
Clinical trials (lead sponsor) 1
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT05392751 | Dose Escalation Study to Evaluate the Safety/Tolerability and Efficacy of EA-2353 in Subjects With Retinitis Pigmentosa | Phase 1/Phase 2 | Terminated | Jun 2, 2022 | Apr 24, 2024 (actual) |